hVIVO (HVO) has launched a new unified brand identity, marking its transition into a fully integrated, end-to-end clinical development partner.
The rebrand follows the integration of Venn Life Sciences, CRS and Cryostore. As a result, all operating companies will now trade under the hVIVO brand, simplifying the group’s structure and reinforcing a single partner model for clients.
The company now offers a fully integrated platform supporting drug development from preclinical strategy through to Phase II and selected Phase III programmes. This is designed to provide continuity across the development pathway and reduce operational complexity.
In addition, the group has structured its offering into four core service lines. Consulting supports early-stage strategy and programme design, while Clinical Trials delivers early phase studies through owned research sites. Human Challenge Trials enable controlled evaluation of vaccines and therapeutics, and Laboratories provide specialist analysis, including virology, immunology and biomarker services.
Importantly, the integrated model is intended to generate faster, higher-quality human data, helping to reduce handoffs and support more efficient trial design.
hVIVO’s Chief Executive Officer Yamin 'Mo' Khan said: “This rebrand reflects our strategic transformation into a purpose-built, full-service international clinical development partner, addressing the industry's need for faster, high-quality data that can de-risk drug development.
“By bringing together consulting, clinical trials, human challenge trials and laboratories into a single, unified platform, we offer clients a seamless pathway from pre-clinical strategy to clinical proof-of-concept, delivered by one expert partner. Our unified brand reinforces the strength of our integrated model, proprietary infrastructure and deep scientific expertise, and our ability to ultimately help pharmaceutical and biotech companies bring important medicines to patients faster.”
View from Vox
The rebrand formalises a shift that has been underway for some time. By integrating its capabilities under one umbrella, hVIVO is positioning itself as a more comprehensive partner in early-stage drug development, which could enhance its appeal to pharmaceutical and biotech clients seeking speed and efficiency.